- Home
- MYNZ
MYNZ
Mainz Biomed N.V.
as 06-06-2025 4:00pm EST
Mainz Biomed NV develops market-ready molecular genetic diagnostic solutions for life-threatening conditions. The company's flagship product is ColoAlert, is an accurate, non-invasive and easy-to-use, early-detection diagnostic test for colorectal cancer based on real-time Polymerase Chain Reaction-based (PCR) multiplex detection of molecular-genetic biomarkers in stool samples. The company operates in one operating segment, genetic diagnostic testing.
| Founded: | 2021 | Country: | Germany |
| Employees: | N/A | City: | N/A |
| Market Cap: | 8.0M | IPO Year: | 2021 |
| Target Price: | $14.00 | AVG Volume (30 days): | 92.3K |
| Analyst Decision: | Buy | Number of Analysts: | 2 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -22.36 | EPS Growth: | N/A |
| 52 Week Low/High: | $1.92 - $34.00 | Next Earning Date: | 06-17-2025 |
| Revenue: | $893,991 | Revenue Growth: | -0.17% |
| Revenue Growth (this year): | 26.06% | Revenue Growth (next year): | 4.97% |
Latest Mainz Biomed N.V. News
MYNZ Breaking Stock News: Dive into MYNZ Ticker-Specific Updates for Smart Investing
GOBankingRates
6 days ago
7 Summer Side Hustles That Can Pay $1,000 a Week or More
Yahoo Finance Video
6 days ago
Will Tesla have to play catch up to Waymo's robotaxis?
Yahoo Finance
6 days ago
Why Scott Bessent wants to make it easier for banks to own Treasurys
The Guardian
6 days ago
When are people too old to do their jobs?
GlobeNewswire
6 days ago
EKOUAER Launches Wedding Season Special Edition and Joins The Knot Registry
GlobeNewswire
6 days ago
Replimune Presents New Analyses from the IGNYTE Study of RP1 plus Nivolumab in Anti-PD1 Failed Melanoma at the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting
PR Newswire
6 days ago
Thyme Care Triples Its Multidisciplinary Care Team with Increased Focus on Often-Overlooked Survivorship Population
CNW Group
6 days ago
Statement by Minister Guilbeault on Portuguese Heritage Month
Compare MYNZ vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "MYNZ Mainz Biomed N.V. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.